India: Yearly Stock Market Performance Insight - 2004

Ultratech Cement posts annual decline with a 1-year decline (1,019.95 → 340.45), down 66.6% cumulatively. Weak margins on 250.6B annual revenue with only 20.5B profit (8.2% margin) in Qtr ending Mar 2025 validate market skepticism. Structural improvements needed before recovery.

Dr. Reddy's experiences yearly pullback with a 1-year decline (146.90 → 86.54), down 41.1% cumulatively. Yet fundamentals remain solid: 85.1B annual revenue generating 15.9B profit (18.7% margin) as of Qtr ending Mar 2025 suggests this could be a value opportunity. Contrarian investors take note.

HFCL encounters consecutive annual declines with a 2-year decline (37.90 → 18.40), down 51.5% cumulatively. Financial struggles compound yearly losses: despite 8.0B annual revenue, - 833.0M losses persist (-10.4% margin) as of Qtr ending Mar 2025. Turnaround remains elusive.

Olectra Greentech sees continued yearly losses with a 2-year decline (15.35 → 7.20), down 53.1% cumulatively. Weak margins on 4.5B annual revenue with only 206.9M profit (4.6% margin) in Qtr ending Mar 2025 validate market skepticism. Structural improvements needed before recovery.

Garnet International struggles through multi-year headwinds with a 4-year decline (160.00 → 1.38), down 99.1% cumulatively. Yet fundamentals remain solid: 19.3M annual revenue generating 3.9M profit (20.0% margin) as of Qtr ending Mar 2025 suggests this could be a value opportunity. Contrarian investors take note.

Morepen Laboratories endures extended market pressure with a 4-year decline (98.00 → 11.00), down 88.8% cumulatively. Weak margins on 4.7B annual revenue with only 203.1M profit (4.4% margin) in Qtr ending Mar 2025 validate market skepticism. Structural improvements needed before recovery.